Cariprazine Publications 2006-2017

Non-clinical

**Chemistry**

Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszály B

**Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors**
*Bioorg Med Chem Lett, **22**:* 3437-3440, 2012

**Neurochemistry**

**Cariprazine (RGH-188), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile**
*J Pharmacol Exp Ther* **333**: 328-340, 2010

**Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography**
*Psychopharmacology* **218**: 579-587, 2011

**In vitro and in vivo comparison of [3H](+)—PHNO and [3H]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites**
Kiss B, Horti F, Bobok A
*Synapse* **65**: 467-478, 2011

**Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11C]-cariprazine: An in vivo positron emission tomography study in non-human primates**
*Synapse* **67**: 258-264, 2013

**Long-Term Effects of Cariprazine Exposure on Dopamine Receptor Subtypes**
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
*CNS Spectrums* **19**: 268-277, 2014

**Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine**
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
*CNS Spectrums*, 1-11, 06 January 2017

**Pharmacology**

**RGH-188, a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents**

*Neurochemistry International* **59**: 925-935, 2011

**Cariprazine, a dopamine D3-receptor-prefering partial agonist, block phenycyclidine-induced impairments of working memory, attention set shifting, and recognition memory in the mouse.**

Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C

*Psychopharmacology* **226**: 91-100, 2013

**Cariprazine (RGH-188), a D3-prefering dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats**

Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z

*Psychopharmacology* **226**: 285-293, 2013

**Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression**

Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I

*Behav Pharmacol* **25**: 567-574, 2014

**Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices**

El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N

*Psychiatry Res* **229**: 370-373, 2015

**Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology**

Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N

*Eur Neuropsychopharmacol* **26**: 3-14, 2016

**The dopamine D3-prefering D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neuro-developmental model for schizophrenia**

Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KC

*Eur Neuropsychopharmacol* **26**: 208-224, 2016

**Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model**

Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS

*Int J Neuropsychopharmacol*, 1-9, 22 May 2017

**Pharmacokinetic**

*Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine*

Pásztor Mészáros G, Ágai-Csongor É, Kapás M


**Clinical**

**Schizophrenia**

*An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial*


*Schizophr Res* **152**: 450-457, 2014
Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial

Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial

Cariprazine in the treatment of schizophrenia: A proof-of-concept trial

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA
Schizophr Res 176: 264-271, 2016

The effect of cariprazine on hostility associated with schizophrenia
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I

Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial
Lancet 389: 1103-1113, 2017

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study
CNS Spectrums 1-12, 08 May 2017

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study
Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Németh G, Migliore R, Volk S
Psychopharmacology 234: 199-209, 2017

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM
Int Clin Psychopharmacol 32: 319-328, 2017

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis
BMC Psychiatry 17: 305, 2017

Mania
The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial
*Bipolar Disord* **17**: 63-75, 2015

**Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo controlled, phase III trial**

**Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder**

**Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials**
Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S

**Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies**
Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, Yatham LN
*J Affect Disord* **215**: 205-212, 2017

**The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study**
*J Affect Disord* **225**: 350-356, 2017

**Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder**
*J Affect Disord*, in press, 2017

**Bipolar Depression**

**An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression**

**Major Depression add-on**

**Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients**

**Human Pharmacokinetic**

**Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO**
*Psychopharmacology* **233**: 3503-3512, 2016
Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

Health Technology Assessment (HTA)

Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone
J Comp Eff Res 1-10, epub ahead of print, 2017

General

Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia.
A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications (Published in Hungarian with English abstract)
Laszlovszky I, Németh G
Gyógyszerészet 59: 643-646, 2015